A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients With Various Solid Cancers With Repeated Administration in Patients With Clinical Benefit
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose
3 weeks
No
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim Pharmaceuticals
Taiwan: Department of Health
1230.16
NCT00969553
August 2009
Name | Location |
---|